PPARγ is an interesting target for cancer therapy not only because of its elevated expression in tumors, but also because PPARγ activation results in decreased cell proliferation, decreased G0/G1 to S phase progression, increased terminal differentiation, and apoptosis [11], [12], [13]. Here, PPARG is linked to cancer.